1. Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group
- Author
-
Hogervorst, Milou Amber, Vreman, Rick, Heikkinen, Inkatuuli, Bagchi, Indranil, Gutierrez-Ibarluzea, Inaki, Ryll, Bettina, Eichler, Hans-Georg, Petelos, Elena, Tunis, Sean, Sapede, Claudine, Goettsch, Wim, Janssens, Rosanne, Huys, Isabelle, Barbier, Liese, DeJean, Deirdre, Strammiello, Valentina, Lingri, Dimitra, Goodall, Melinda, Papadaki, Magdalini, Toussi, Massoud, Voulgaraki, Despina, Mitan, Ania, Oortwijn, Wija, Hogervorst, Milou Amber, Vreman, Rick, Heikkinen, Inkatuuli, Bagchi, Indranil, Gutierrez-Ibarluzea, Inaki, Ryll, Bettina, Eichler, Hans-Georg, Petelos, Elena, Tunis, Sean, Sapede, Claudine, Goettsch, Wim, Janssens, Rosanne, Huys, Isabelle, Barbier, Liese, DeJean, Deirdre, Strammiello, Valentina, Lingri, Dimitra, Goodall, Melinda, Papadaki, Magdalini, Toussi, Massoud, Voulgaraki, Despina, Mitan, Ania, and Oortwijn, Wija
- Abstract
ObjectivesUncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface. MethodsSix online discussions among WG members (Dec 2021-Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions. ResultsThe WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: "unavailable," "inaccurate," "conflicting," "not understandable," "random variation," "information," "prediction," "impact," "risk," "relevance," "context," and "judgment." These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed. ConclusionsThe systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.
- Published
- 2023